We retrospectively compared the incidence of acute graftversus-host disease (GVHD) before and after September 1999, when we changed the mode of cyclosporine A (CsA) administration from twice-daily infusions (TD) (n ¼ 58) to continuous infusion (CIF) (n ¼ 71). The incidence of grade II-IV acute GVHD in the CIF group (56%) was significantly higher than that in the TD group (27%, P ¼ 0.00022). Multivariate analysis identified only two independent significant risk factors for the development of grade II-IV acute GVHD; CIF of CsA (relative risk 2.59, 95% CI 1.46-4.60, P ¼ 0.0011) and the presence of HLA mismatch (2.01, 95% CI 1.15-3.53, P ¼ 0.014). The incidence of relapse was significantly lower in the CIF group when adjusted for disease status before transplantation (0.41, 95% CI 0.18-0.95, P ¼ 0.038), which resulted in better disease-free survival in high-risk patients (43 vs 16% at 2 years, P ¼ 0.039), but not in standard-risk patients (72 vs 80%, P ¼ 0.45). CIF of CsA with a target level of 250-400 ng/ml may not be appropriate for GVHD prophylaxis in standard-risk patients.
closporine A; graft-versus-host disease; continuous infusion Cyclosporine A (CsA) is a mainstay of treatment in the pharmacologic prevention of graft-versus-host disease (GVHD), and is usually combined with methotrexate (MTX). However, the dose, target blood level, and schedule of administration vary among protocols. 1 In particular, it has not been assessed whether CsA should be administered as a continuous infusion (CIF) or as twice-daily infusions (TD) in the early period after transplantation when patients cannot tolerate an oral intake. In September 1999, we changed the mode of CsA administration from TD to CIF, without major changes to other transplantation procedures. The aim of this study was to evaluate the impact of these two different modes of administration on the incidence of acute GVHD.
Patients and methods

Patients
We retrospectively analyzed the records of adult patients who underwent allogeneic hematopoietic stem cell transplantation for the first time between June 1995 and May 2000 using a GVHD prophylaxis regimen consisting of CsA and MTX. During that time, this combination was the standard regimen for GVHD prophylaxis in our center, but CsA alone was used for patients who were at a very high risk for relapse, and a combination of tacrolimus and MTX was used for patients who had received a graft from an unrelated donor with at least one allele or antigen mismatch. Those who received a T-cell-depleted graft and those who received a reduced-intensity conditioning regimen or a conditioning regimen that included ATG or CAMPATH1-H were excluded. Otherwise, consecutive patients were included in the study. The data for 129 patients were analyzed. There were 95 males and 34 females with a median age of 38 years (range 18-60). Bone marrow (BM) was exclusively used in unrelated transplants, whereas 13 related donors chose a collection of G-CSF-mobilized peripheral blood stem cells (PBSC) rather than a BM harvest. BM was additionally harvested from poor mobilizers.
Transplantation procedure
Conditioning was mainly a combination of cyclophosphamide (60 mg/kg for 2 days) with either busulfan (4 mg/kg/day for 4 days) or total body irradiation (TBI; 2 Gy twice daily for 3 days). GVHD prophylaxis was with CsA and short-term MTX (10-15 mg/m 2 on day 1 and 7-10 mg/m 2 on days 3 and 6, and optionally on day 11), with a starting dose of CsA of 3 mg/kg/day. Before September 1999, CsA was administered as a 4 h infusion twice daily in equally divided doses. The dose of CsA was adjusted to maintain the trough blood CsA concentration between 150 and 300 ng/ml. After September 1999, CsA was administered as a CIF. The dose of CsA was adjusted to maintain the blood CsA concentration between 250 and 400 ng/ml. CsA concentration was measured at least once a week by fluorescence polarization immunoassay with a specific monoclonal antibody, using whole blood samples. 2 Metabolites of CsA were not measured by this method. The route of CsA administration was converted to oral at a ratio of 1:2 or 1:3 when patients were able to tolerate oral intake at least 3 weeks after transplantation. Acute GVHD was graded as previously described. 3 Prophylaxis against bacterial, fungal, and pneumocystis carinii infection consisted of fluconazole, tosufloxacin, and sulfamethoxazole/trimethoprim. As prophylaxis against herpes simplex virus infection, acyclovir was given from day À7 to 35. Pre-emptive therapy for cytomegalovirus infection was with ganciclovir, while monitoring cytomegalovirus antigenemia. 4 
Statistical considerations
Standard-risk disease was defined as acute leukemia in complete remission, chronic myelocytic leukemia in the first chronic phase, chemosensitive lymphoma, and myelodysplastic syndrome comprising refractory anemia or refractory anemia with ringed sideroblasts, while others were considered high-risk diseases. Renal dysfunction was defined as an elevation in serum creatinine level to above Â 1.5 or Â 2.0 the baseline value, except for that clearly caused by the administration of amphotericin B. Patients who received both BM and PBSC grafts were included in the PBSC group.
Probabilities and continuous variables in the two groups were compared using Fisher's exact test and the MannWhitney U-test, respectively. Cumulative incidences of acute GVHD and relapse were calculated using Gray's method, considering death without acute GVHD or relapse, as a competing risk. 5 Disease-free survival was estimated using the Kaplan-Meier method. Potential confounding factors considered in the analysis were age, sex, donor type (related or unrelated), stem cell source (BM or PBSC), disease risk, conditioning regimen, HLA mismatch, total dose of MTX, and mode of CsA administration.
Results
Patient characteristics
Of the 129 patients analyzed, 58 and 71 patients were in the TD and CIF groups, respectively. The CIF group included a significantly higher proportion of patients with high-risk disease (P ¼ 0.021), those transplanted from an unrelated donor (P ¼ 0.004), those who received an HLA-mismatched graft (P ¼ 0.023), and those who received a PBSC graft (P ¼ 0.0061) ( Table 1 ). The total dose of MTX was significantly lower in the CIF group (median dose 35 mg/m 2 vs 33 mg/m 2 , P ¼ 0.0002). Other characteristics were equivalent between the two groups.
Risk factors for grade II-IV acute GVHD
First, we performed a univariate analysis to evaluate the impact of potential confounding factors on the incidence of grade II-IV acute GVHD. As shown in Table 2 , transplant from an unrelated donor, the presence of HLA mismatch, the use of a TBI-containing regimen, a lower total dose of MTX, and CIF of CsA were identified as significant risk factors for the development of grade II-IV acute GVHD. The incidence of grade II-IV acute GVHD in the CIF group (56%) was significantly higher than that in the TD group (27%, P ¼ 0.00022, Figure 1 ). Next, we performed a multivariate analysis using the backward stepwise selection method to identify independent risk factors for the development of grade II-IV acute GVHD. Only two factors, CIF of CsA (relative risk 2.59; 95% CI 1.46-4.60, P ¼ 0.0011) and the presence of HLA mismatch (2.01; 95% CI 1.15-3.53, P ¼ 0.014), were identified as independent significant risk factors (Table 3A) . The impact of these two factors was significant even when adjusted for the total dose of MTX and donor type (Table 3B) .
Renal toxicity
Renal dysfunction was significantly less frequent in the CIF group than the TD group: 27% vs 66% (Po0.0001) and 13% vs 41% (P ¼ 0.0002), when we defined renal dysfunction as an elevation of the serum creatinine level to above Â 1.5 and Â 2.0 the baseline value, respectively (Table 4) .
Actual daily dose of CsA
We adjusted the dose of CsA to maintain the target blood level as described above. We compared the actual daily dose of CsA, excluding patients who were converted to oral administration. The actual daily dose of CsA in the CIF Continuous vs twice-daily CsA for GVHD prophylaxis N Ogawa et al group was consistently significantly lower than that in the TD group during the first 4 weeks after transplantation ( Figure 2 ).
Transplant outcome
The CIF of CsA was shown to significantly decrease the incidence of relapse, after adjusting for disease status before transplantation (relative risk 0.41, 95% CI 0.18-0.95, P ¼ 0.038). This resulted in significantly better disease-free Continuous vs twice-daily CsA for GVHD prophylaxis N Ogawa et al survival in the CIF group than in the TD group among high-risk patients (43 vs 16% at 2 years, P ¼ 0.039, Figure 3 ), whereas there was no significant difference in disease-free survival between the two groups among standard-risk patients (72 vs 80% at 2 years, P ¼ 0.45).
Discussion
To summarize the findings of this study, the CIF of CsA with a target level of 250-400 ng/ml significantly increased the incidence of grade II-IV acute GVHD, but significantly decreased the incidences of renal dysfunction and relapse, which resulted in better disease-free survival in high-risk patients. However, disease-free survival was not improved in standard-risk patients, probably because the incidence of relapse was originally low in these patients. Therefore, this mode of CsA administration may not be appropriate for standard-risk patients. There are at least two possible explanations for why the incidence of acute GVHD was higher in the CIF group. First, the total dose (or the area under the curve) of CsA may be important. Second, it may be important to achieve a peak CsA concentration. It was impossible to draw a definite conclusion from this study. However, considering that the actual daily dose of CsA was gradually decreased in the CIF group after transplantation, a target level of 250-400 ng/ml might be too low to prevent GVHD adequately, although this target level has been used in recent large randomized controlled trials. 6, 7 Miller et al 8 adjusted the dose of CsA as a CIF to maintain the blood CsA level between 450 and 520 ng/ml. In this setting, the mean actual dose of CsA was maintained between 2.87 and 3.15 mg/kg during the first 4 weeks after transplantation. Therefore, this higher target level may be more appropriate when comparing the mode of CsA administration, although it needs to be confirmed by measuring the area under the curve. The major shortcoming of this study was that this was not a randomized controlled trial and there were some uncontrolled variables that might have caused bias. However, the impact of the mode of CsA administration remained significant after adjusting for these uncontrolled variables, as shown in Table 3B . We are planning a randomized controlled trial to confirm these results. 
